Ferrari NV vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Ferrari NV trades at $388.84 (market cap $67.35B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.7 (market cap $2.27B). The key difference: Ferrari NV is far larger — about 29.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Ferrari NV pays a 1.09% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| RACE | SLS | |
|---|---|---|
Market Cap | $67.35B | $2.27B |
Volume | 390,618 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $15.46 |
52-Week Low | $314.63 | $1.39 |
Typical Hold Time | 126 Days | — |
Enterprise Value | $69.22B | $2.14B |
Dividend Yield | 1.09% | — |
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $390.13, up 0.97% today, with a bearish technical signal but strong fundamentals including 22.25% net income margin and consistent earnings beats. Revenue grew to $7.15B in 2025, and the company is executing a share buyback program. Analyst consensus is bullish with a $462.75 price target, though technical indicators show resistance near $390.
The stock offers upside based on premium brand strength and profitability, but faces risks from high valuation multiples (P/E 37.19) and economic sensitivity. Institutional accumulation and positive media coverage support sentiment, yet investors should weigh technical resistance against fundamental growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →